FOXP1 abnormalities in lymphoma: Translocation breakpoint mapping reveals insights into deregulated transcriptional control

Modern Pathology

Volumn 21, Issue 7, 2008, Pages 902-911

  Goatly, Alison ^a   Bacon, Chris M ^a   Nakamura, Shotaro ^b   Ye, Hongtao ^a   Kim, Insun ^c   Brown, Philip J ^d   Ruskoné Fourmestraux, Agnès ^e   Cervera, Pascale ^e   Streubel, Berthold ^f   Banham, Alison H ^d   Du, Ming Qing ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KYUSHU UNIVERSITY   (Japan)

^c Korea University College of Medicine   (South Korea)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e HÔPITAL SAINT ANTOINE   (France)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chromosome translocation; FOXP1; FOXP1 expression; Lymphoma

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN HEAVY CHAIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER LOCALIZATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOXP1 GENE; GASTRECTOMY; GENE MAPPING; GENE TRANSLOCATION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; ONCOGENE; PRIORITY JOURNAL; UNTRANSLATED REGION;

CHROMOSOME BREAKAGE; CHROMOSOME MAPPING; DNA, NEOPLASM; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASMS, SECOND PRIMARY; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC;

EID: 46049096355     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.74     Document Type: Article

References (20)

1. Hu H, Wang B, Borde M, et al. FOXP1 is an essential transcriptional regulator of B cell development. Nat Immunol 2006;7:819-826.
2. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002;2:920-932.
3. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
4. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005;11:1065-1072.
5. Barrans SL, Fenton JA, Banham A, et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004;104:2933-2935.
6. Sagaert X, De Paepe P, Libbrecht L, et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 2006;24:2490-2497.
7. Streubel B, Vinatzer U, Lamprecht A, et al. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005;19:652-658.
8. Wlodarska I, Veyt E, De Paepe P, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005;19:1299-1305.
9. Fenton JA, Schuuring E, Barrans SL, et al. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2006;45:164-168.
10. Haralambieva E, Adam P, Ventura R, et al. Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 2006;20:1300-1303.
11. Remstein ED, Dogan A, Einerson RR, et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006;30:1546-1553.
12. Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 2003;102:1012-1018.
13. Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994;5:397-400.
14. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-577.
15. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002;3:97-104.
16. Ye H, Gong L, Liu H, et al. MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol 2005;205:293-301.
17. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-653.
18. Pajer P, Pecenka V, Kralova J, et al. Identification of potential human oncogenes by mapping the common viral integration sites in avian nephroblastoma. Cancer Res 2006;66:78-86.
19. Brown PJ, Ashe SL, Leich E, et al. Potentially oncogenic B-cell activation induced smaller isoforms of FOXP1 are highly expressed in the activated B-cell-like subtype of DLBCL. Blood 2008;111:2816-2824.
20. Wang B, Lin D, Li C et al. Multiple domains define the expression and regulatory properties of FOXP1 forkhead transcriptional repressors. J Biol Chem 2003;278:24259-24268.